AMENDMENT NO. 1 TO PATENTS SUB-LICENSE AGREEMENTPatents Sub-License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJanuary 13th, 2021 Company IndustryThis Amendment No. 1 to Patents Sub-License Agreement (“Amendment No. 1”), effective as of 26 May 2020 (“Amendment No. 1 Effective Date”), is entered into by and between LA SOCIETE PULSALYS, a company organized under French Law, having its registered office at [***] (“Pulsalys”), Cobalt Biomedicine, Inc. a Delaware corporation having offices at [***] (“Cobalt”), and Sana Biotechnology, Inc. a Delaware corporation having offices at 188 East Blaine St., Seattle WA, 98102 (“Sana”).
CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 3 TO PATENTS SUB-LICENSE AGREEMENTPatents Sub-License Agreement • November 8th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledNovember 8th, 2023 Company IndustryThis Amendment No. 3 to Patents Sub-License Agreement (“Amendment No. 3”), effective as of 31 July 2023 (“Amendment No. 3 Effective Date”), is entered into by and between LA SOCIETE PULSALYS, a company organized under French Law, having its registered office at [***] (French company registration number) [***], Code [***] (French principal activity code) [***] (“Pulsalys”) and Sana Biotechnology, Inc. a Delaware corporation having offices at 188 East Blaine St., Seattle WA, 98102 (“Sana”).
PATENTS SUB-LICENSE AGREEMENTPatents Sub-License Agreement • January 13th, 2021 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledJanuary 13th, 2021 Company IndustryThe Centre International de Recherche en Infectiologie (hereinafter the “LABORATORY”) in collaboration with Paul Ehrlich Institute has developed a technology entitled [***] which has been the subject of a European patent application number [***], filed on [***], in the names of [***] (hereinafter referred to as the “CO-OWNERS”). For the avoidance of doubt, Paul Ehrlich Institute has no ownership interest in the PATENTS (as defined below).
AMENDMENT NO. 2 TO PATENTS SUB-LICENSE AGREEMENTPatents Sub-License Agreement • November 2nd, 2022 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledNovember 2nd, 2022 Company IndustryThis Amendment No. 2 to Patents Sub-License Agreement (“Amendment No. 2”), effective as of 16 August 2018 (“Amendment No. 2 Effective Date”), is entered into by and between LA SOCIETE PULSALYS, a company organized under French Law, having its registered office at [***] (French company registration number) [***], Code [***] (French principal activity code) [***] (“Pulsalys”) and Sana Biotechnology, Inc. a Delaware corporation having offices at 188 East Blaine St., Seattle WA, 98102 (“Sana”).